<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405584</url>
  </required_header>
  <id_info>
    <org_study_id>rjkls2017196</org_study_id>
    <nct_id>NCT03405584</nct_id>
  </id_info>
  <brief_title>High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment</brief_title>
  <official_title>Efficacy of High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment：a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual therapy for Helicobacter Pylori including a proton pump inhibitor (PPI) and amoxicillin.
      Amoxicillin has low resistance rate as well as low percentage of side effects. No trial has
      examined the the efficacy of high dose of dual therapy plus bismuth for H. pylori
      treatment.This study is designed to evaluate the efficacy and safety of the addition of
      bismuth to high dose of dual therapy for H. pylori eradication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication rate</measure>
    <time_frame>Six weeks after completion of therapy</time_frame>
    <description>Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was defined as negative result from urea breath test (&lt;4‰) (4‰ as the cutoff value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse effects</measure>
    <time_frame>Within 7 days after completion of therapy.</time_frame>
    <description>The subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as &quot;mild&quot; (transient and well tolerated), &quot;moderate&quot; (causing discomfort and partially interfering with daily activities), or &quot;severe&quot; (causing considerable interference with daily activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance rate</measure>
    <time_frame>Within 7 days after completion of therapy.</time_frame>
    <description>Compliance was defined as poor when they had taken less than 80% of the total medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Bismuth Plus Dual Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Proton pump inhibitor</description>
    <arm_group_label>Bismuth Plus Dual Therapy</arm_group_label>
    <arm_group_label>Dual Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Antibiotic for H. pylori eradication</description>
    <arm_group_label>Bismuth Plus Dual Therapy</arm_group_label>
    <arm_group_label>Dual Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Potassium Citrate</intervention_name>
    <description>Gastric mucosal protective drug with anti-H. pylori effect</description>
    <arm_group_label>Bismuth Plus Dual Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with non-ulcer functional dyspepsia or peptic ulcer disease

          -  Ability and willingness to participate in the study and to sign and give informed
             consent

          -  Confirmed H. pylori infection

        Exclusion Criteria:

          -  Less than 18 years old

          -  With previous gastric surgery

          -  Major systemic diseases

          -  Pregnancy or lactation

          -  Allergy to any of the study drugs Administration of antibiotics, bismuth,
             antisecretory drugs in 8 weeks prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Lu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lou Yu, M.D</last_name>
    <phone>86+18202105517</phone>
    <email>yulousjtu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lou Yu, M.D.</last_name>
      <phone>86+18202105517</phone>
      <email>yulousjtu@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Lu, M.D.,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lou Yu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao Liang, M.D.,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaohua Long, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laisheng Luo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hong Lu, MD</investigator_full_name>
    <investigator_title>Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

